Gives the HHS Secretary authority to review brand-name drug prices each year and declare prices “excessive” using an international reference test and other factors. When a drug is found excessive, the Secretary can void or waive government-granted exclusivities and issue open, non‑exclusive licenses so other makers can use the drug and rely on the regulatory data; licenses must include reasonable royalties and require sales below the excessive price. The bill also creates mandatory annual manufacturer reporting, a public database of excessive-price findings, expedited review for generic/biosimilar applicants that rely on issued licenses, civil enforcement (including recovery of excess revenues), and an antitrust prohibition on conduct that would block these licenses.